Drug Trial Radar · NCT05451667
Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Jan 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Aug 15, 2022
Primary completion
Dec 20, 2022
Study completion Dec 20, 2022
Sponsor
- Lead sponsor
- Yuejia Pharmaceuticals (USA), Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Zhejiang Yuejia Pharmaceuticals Co., Ltd.
- First posted
- Jul 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase I, randomized, double-blind, placebo controlled study is to investigate the safety, tolerability and pharmacokinetics (PK) of topically administered YJ001 in a single-ascending dose (SAD) fashion in healthy volunteers between 18 to 55 years of age, to establish the dosage range for spray use, and to provide a dosage regimen for Phase I multiple-ascending dose (MAD) study in healthy subjects. The study is to enroll 4 cohorts, the doses of which are 148, 296, 552 and 828 mg, with the option to enroll 2 additional cohorts (8 subjects for each cohort) without requiring a protocol amendment. Subjects will be screened between Day -28 and Day -2 and will be admitted to the clinic on Day -1. Subjects will be housed within the clinic from Day -1 through Day 8 and will be discharged on Day 8 after all scheduled study procedures have been completed.
Conditions
- Safety and Tolerability
Interventions
YJ001 for Spray UseDrug
YJ001 (active ingredient)
Placebo of YJ001 for Spray UseDrug
Hydroxypropyl Methylcellulose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and significant laboratory abnormalityTime frame: Day -28 to Day 8
- Systemic exposure of the 4 analytes to be assayedTime frame: Day 1 to Day 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC, Inc.
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.